Exeter Respiratory Research & Innovation (ERI)

Exeter Respiratory Research & Innovation (ERI)

In category: *Show all*


Cough Study: A Double-blind, Randomised, Placebo controlled, Two period Cross-over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

We are testing an investigational medicine called orvepitant as a treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a condition that causes scarring of the lungs. An investigational medicine does not yet have a license to be marketed or sold. It is still being tested to see if it works and to make […]


View


OXYPuF: Ambulatory Oxgyen Therapy for Pulmonary Fibrosis

Primary Objective: To determine what is the clinical and cost effectiveness of ambulatory oxygen therapy (AOT) in patients with idiopathic pulmonary fibrosis (IPF) Inclusion Criteria: Clinically diagnosed IPF, confirmed by an ILD MDT linked to an NHS specialist commissioned IPF service Breathlessness with MRC dyspnoea score ≥2 Click here to Read a Summary of this […]


View


Widening participation for orphan drug trials

Orphan drugs are medicines for diagnosis, prevention or treatment of life-threatening or progressive disorders that are rare (affecting less than 1 in 2,000 people). An example is Idiopathic Pulmonary Fibrosis (IPF). We are approaching a number of people who have Idiopathic Pulmonary Fibrosis (IPF) to learn more about how and why they have or have […]


View


ASPEN: Randomised study to assess the effect of Brensocatib in patients with NCFBE

The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for NCFBE. This is an experimental clinical research study of a study drug called brensocatib. “Experimental” means that the study drug is currently being tested in clinical research studies, and has not been approved for use in the […]


View


INJUSTIS: It’s Not JUST Idiopathic Pulmonary FibrosiS Study

Fibrotic lung conditions result in scarring of the lung tissue. This causes shortness of breath and cough, and has an enormous impact on people’s quality of life. We currently know that progressive lung scarring may be caused by a few conditions like Rheumatoid Arthritis and previous exposure to asbestos, birds (pigeons, parrots and budgies particularly) […]


View


MucAct COPD Study

Some patients with Chronic Obstructive Pulmonary Disease (COPD) find it hard to clear sputum (phlegm) from the airways. Unfortunately, there’s no good evidence that shows the best treatment for patients. We want to study whether breathing in sodium chloride (salty water) through a nebuliser can help patients with COPD cough up phlegm, make them feel […]


View


TIPAL: Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole

Idiopathic Pulmonary Fibrosis is a disease which results in damage to the lung tissue. It is characterised by progressive loss of lung function (measured by breathing tests) and increasing breathlessness. It is incurable and there are few available treatments. It is thought to occur because of tiny “scars” (which we call fibrosis) that develop throughout […]


View